Ambulatory surgery provides a faster clinical benefit for patients with hidradenitis suppurativa (HS) who do not respond fully to medical therapies, according to clinical data and surgical guidelines. While new biologic treatments have expanded management options, surgical intervention remains a primary method for removing diseased tissue and reducing the frequency of painful flares in affected areas.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful lumps, abscesses, and tunneling under the skin, typically in the armpits, groin, and under the breasts. The American Academy of Dermatology notes that the condition often leads to significant scarring and psychological distress, requiring a multidisciplinary approach to care.
Medical management has evolved with the introduction of interleukin-17 and interleukin-1 inhibitors, but these therapies often target systemic inflammation rather than the physical tunnels (sinus tracts) already formed in the skin. Surgery addresses these structural changes directly, offering a level of immediate relief that medication cannot provide.
How does ambulatory surgery help manage HS?
Ambulatory surgery for HS focuses on the removal of affected skin and the closure of sinus tracts. Unlike systemic medications, which aim to prevent new lesions, surgical excision removes existing diseased tissue that is prone to recurring infections. According to the National Library of Medicine, wide excision of the affected area is often the most effective way to prevent recurrence in a specific anatomical site.
Common ambulatory procedures include:
- Incision and Drainage: Used for acute flares to relieve pressure and pain, though it does not treat the underlying disease.
- Deroofing: A technique where the “roof” of a sinus tract is removed, allowing the tract to heal from the bottom up. This is often preferred for smaller areas to preserve healthy skin.
- Wide Local Excision: The removal of the entire affected skin area, followed by closure. This is typically reserved for more advanced stages of the disease where the skin is heavily scarred.
These procedures are increasingly performed in ambulatory settings, meaning patients can undergo the surgery and return home the same day. This reduces the risks associated with prolonged hospitalization and lowers overall healthcare costs.
Why choose surgery over new biologic therapies?
Recent FDA approvals have introduced several biologics that target specific pathways of inflammation. However, these drugs do not “undo” the physical damage caused by HS. Once a sinus tract has formed, it acts as a reservoir for bacteria and inflammation, which can lead to persistent drainage regardless of the medication used.
Surgical intervention provides a “faster clinical benefit” because it physically eliminates the source of the drainage and pain. For patients with localized disease—where the condition is confined to one or two specific areas—surgery can lead to long-term remission in those spots. According to guidelines from the HS Foundation, the goal of surgery is to improve the patient’s quality of life by reducing the daily burden of wound care and pain management.
The decision between surgery and medical therapy often depends on the Hurley Stage of the disease:
- Hurley Stage I: Solitary or few abscesses without sinus tracts. Medical therapy is usually the first line.
- Hurley Stage II: Recurrent abscesses with sinus tracts and scarring. A combination of biologics and targeted surgery (like deroofing) is often recommended.
- Hurley Stage III: Diffuse and interconnected sinus tracts over large areas. Extensive surgical excision may be necessary to achieve clinical control.
What are the risks and recovery expectations?
Surgical recovery for HS varies depending on the extent of the tissue removed. Wide excision requires a longer healing period and may involve wound vacuums or skin grafts to close large gaps. Patients are typically advised to avoid strenuous activity for several weeks to prevent the surgical site from reopening.
Potential risks include infection at the surgical site, hematoma, and the possibility of the disease returning in adjacent areas. Because HS is a systemic inflammatory condition, surgery treats the “symptom” (the lesion) rather than the “cause” (the immune response). Therefore, many physicians recommend continuing medical therapy after surgery to prevent new lesions from forming in healthy skin.
Post-operative care often includes specialized wound dressings and physical therapy to maintain mobility, especially if the surgery occurred near a joint such as the axilla (armpit) or inguinal (groin) region.
Comparing Medical vs. Surgical Approaches
| Feature | Biologic Therapies | Ambulatory Surgery |
|---|---|---|
| Primary Goal | Reduce systemic inflammation | Remove diseased tissue/tracts |
| Speed of Relief | Gradual (weeks to months) | Immediate for the specific site |
| Effect on Scarring | Prevents new scars | Removes existing scarred tissue |
| Duration of Effect | Requires ongoing dosing | Permanent removal of that lesion |
Patients are encouraged to consult with a dermatologist and a plastic or general surgeon to determine the optimal timing for these interventions. Often, a “medical-first” approach is used to stabilize the skin before surgery, which can reduce the risk of complications during the healing process.
For more information on current treatment protocols, patients can visit the official portals of the American Academy of Dermatology or the Centers for Disease Control and Prevention for general skin health guidelines.
The next major milestone for HS treatment will be the release of further long-term data from ongoing clinical trials regarding the efficacy of combined biologic and surgical “hybrid” protocols. Readers are encouraged to share their experiences with HS management in the comments below.